179 related articles for article (PubMed ID: 37717115)
1. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism.
Fujimoto M; Watanabe S; Igarashi K; Ruike Y; Ishiwata K; Naito K; Ishida A; Koshizaka M; Suzuki S; Shiko Y; Koide H; Yokote K
Int J Hypertens; 2023; 2023():6453933. PubMed ID: 36704237
[TBL] [Abstract][Full Text] [Related]
3. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
[TBL] [Abstract][Full Text] [Related]
4. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
Kario K; Nishizawa M; Kato M; Ishii H; Uchiyama K; Nagai M; Takahashi N; Asakura T; Shiraiwa T; Yoshida T; Kaneshiro M; Taguchi T; Shiosakai K; Sugimoto K
Hypertens Res; 2023 Jul; 46(7):1782-1794. PubMed ID: 37173430
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
[TBL] [Abstract][Full Text] [Related]
7. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
[TBL] [Abstract][Full Text] [Related]
9. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
[TBL] [Abstract][Full Text] [Related]
11. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
[TBL] [Abstract][Full Text] [Related]
12. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels.
Yoshida Y; Fujiki R; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Mori Y; Matsuda N; Noguchi T; Nakama H; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2023 Jan; 46(1):100-107. PubMed ID: 36229529
[TBL] [Abstract][Full Text] [Related]
13. Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.
Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
Hypertens Res; 2022 Jan; 45(1):97-105. PubMed ID: 34650195
[TBL] [Abstract][Full Text] [Related]
14. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
15. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Ding K; Li Z; Lu Y; Sun L
Eur J Intern Med; 2023 Sep; 115():114-127. PubMed ID: 37328398
[TBL] [Abstract][Full Text] [Related]
17. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
18. Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism.
Ishikawa T; Morimoto S; Ichihara A
Hypertens Res; 2022 Mar; 45(3):496-506. PubMed ID: 34961793
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
[TBL] [Abstract][Full Text] [Related]
20. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
